New guidelines aim to make prostate cancer screening smarter, not just more frequent

NCT ID NCT04782713

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested new guidelines for PSA screening to help doctors decide when to start and stop screening, how often to repeat it, and when to refer for biopsy. Researchers also provided patient navigation for men with elevated PSA levels. The goal was to see if these steps could reduce unnecessary biopsies and focus on cancers that truly need treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to smarter, safer PSA screening that catches dangerous prostate cancers while avoiding unnecessary biopsies.

What could go wrong

This was a small, completed study with only 49 participants, so results may not apply to larger or more diverse populations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pleomorphic adenoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mile Square Health Center

    Chicago, Illinois, 60612, United States